High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.
J Virol
; 82(9): 4680-4, 2008 May.
Article
em En
| MEDLINE
| ID: mdl-18287240
ABSTRACT
Gene therapy is proposed as a novel therapeutic strategy for treating glioblastoma multiforme (GBM), a devastating brain cancer. In the clinic, antivector immune responses pose formidable challenges. Herein we demonstrate that high-capacity adenovirus vectors (HC-Ads) carrying the conditional cytotoxic gene herpes simplex virus type 1-thymidine kinase (TK) induce tumor regression and long-term survival in an intracranial glioma model, even in the presence of systemic antiadenovirus immunity, as could be encountered in patients. First-generation Ad-TK failed to elicit tumor regression in this model. These results pave the way for implementing HC-Ad-TK-mediated gene therapy as a powerful adjuvant for treating GBM.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Timidina Quinase
/
Terapia Genética
/
Adenoviridae
/
Glioblastoma
/
Vetores Genéticos
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Estados Unidos